A cross-party group of MPs has delivered a scathing verdict on the Government’s strategy for deploying the weight-loss drug Mounjaro, warning that current plans lack ambition and will deny treatment to the vast majority of eligible patients. The Health and Social Care Committee said the phased rollout announced by NHS England is “unambitious” and will reach a “woefully small number of people” compared to the scale of clinical need. Members are demanding an “urgent” acceleration of the programme to prevent the health service from squandering a generational opportunity to tackle the obesity crisis.
A strategy out of step with demand
The committee’s report, published today, lays bare the disconnect between the prevalence of obesity in England and the capacity of the NHS to treat it. Mounjaro, known generically as tirzepatide, has been hailed as a breakthrough in metabolic medicine. Clinical trials demonstrated average weight reductions of more than 20 per cent, outcomes that approach bariatric surgery without the operative risk. The National Institute for Health and Care Excellence (NICE) gave the green light for its use in specific patient cohorts earlier this year, triggering a mandatory funding obligation for the NHS.
Yet the implementation framework published by NHS England proposes a staggered introduction over twelve years. Only an estimated 220,000 patients are expected to gain access in the first three years. That figure represents a fraction of the 3.4 million people in England who meet the clinical criteria for the medication — those with a BMI over 35 and at least one weight-related comorbidity, or a BMI over 30 where other interventions have failed.
The committee heard evidence that the primary bottleneck is not the cost of the drug itself, which carries a list price of roughly £170 per month, but the absence of specialist weight management services required to prescribe and monitor it safely. NICE guidance stipulates that Mounjaro must be initiated within a tier 3 or tier 4 weight management clinic. Provision of these services is patchy at best; vast swathes of the country have no specialist clinics at all.
Workforce and infrastructure gaps
Witnesses told the inquiry that the NHS simply does not have the dietitians, psychologists, specialist nurses, and physicians to staff the expanded clinics the rollout demands. Training pipelines are years behind schedule. The report notes that even if funding were unlocked tomorrow, the workforce does not exist to deliver the care model NICE has mandated.
This structural deficit has created a perverse incentive. Integrated Care Boards (ICBs), tasked with local implementation, are reportedly hesitating to commission new services because they cannot recruit the staff to run them. The result is a de facto rationing mechanism that has nothing to do with clinical prioritisation and everything to do with administrative capacity.
The committee was particularly critical of the lack of a national workforce plan aligned to the obesity strategy. While the NHS Long Term Workforce Plan addresses nursing and medical shortages broadly, it contains no specific targets for the multidisciplinary teams required for complex weight management. MPs described this as a “strategic blind spot” that renders the twelve-year timeline not merely cautious, but effectively fictional.
The case for primary care prescribing
A significant portion of the report explores whether the prescribing restrictions are proportionate to the risk. Mounjaro’s side-effect profile — predominantly gastrointestinal — is well characterised and generally manageable. Several expert witnesses argued that stable patients could be safely managed in primary care with shared-care protocols, freeing specialist clinics for complex cases.
The committee recommends that NHS England and the General Medical Council urgently develop a framework for GP prescribing with specialist oversight. Such a model, they argue, would dramatically expand access without compromising safety. It would also align with the direction of travel for other chronic disease management, where shared care is the norm rather than the exception.
Resistance from some royal colleges has centred on liability and workload. The report acknowledges these concerns but dismisses them as surmountable. “If we can manage anticoagulation and biologics in general practice,” one MP remarked during the evidence sessions, “we can manage a once-weekly injection with a known side-effect profile.” The committee wants a pilot programme launched within six months.
Economic modelling under scrutiny
The twelve-year rollout is predicated on economic modelling that the committee describes as “opaque and potentially flawed.” NHS England’s impact assessment assumes a steady-state uptake and does not fully account for the downstream savings from avoided bariatric surgery, joint replacements, cardiovascular events, and diabetes complications. Independent analyses submitted to the inquiry suggest the drug could be cost-saving within five years if targeted at the highest-risk cohorts.
MPs are demanding that the Department of Health and Social Care publish the full modelling assumptions and subject them to external review. They also want the Treasury to treat obesity medication spend as an invest-to-save category in the upcoming Spending Review, rather than a pure cost pressure on the NHS budget. The distinction is more than semantic; it determines whether ICBs can access transformation funding to build the services they currently lack.
Why it Matters
Obesity costs the UK an estimated £98 billion annually in lost productivity, social care, and NHS treatment. Mounjaro represents the first pharmacological tool capable of delivering clinically meaningful weight loss at population scale — but only if the health system can deliver it. The current plan condemns millions to preventable disease while the NHS perfects a service model it has had years to build. That is not caution; it is a policy failure measured in shortened lives.
